Arbutus Biopharma (ABUS) Rating Lowered to Sell at BidaskClub

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other research analysts have also commented on ABUS. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a report on Monday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma in a report on Wednesday, September 20th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. JMP Securities reaffirmed an “outperform” rating and issued a $13.00 price target (up from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 price target (up from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $13.00.

Arbutus Biopharma (NASDAQ ABUS) opened at $5.55 on Friday. Arbutus Biopharma has a fifty-two week low of $2.35 and a fifty-two week high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.

In related news, insider Michael J. Sofia sold 10,000 shares of Arbutus Biopharma stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total value of $80,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

Large investors have recently modified their holdings of the stock. OxFORD Asset Management LLP lifted its position in Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares during the last quarter. Bank of Montreal Can lifted its position in Arbutus Biopharma by 1.9% in the 2nd quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after purchasing an additional 16,535 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Arbutus Biopharma in the 2nd quarter valued at about $478,000. Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma in the 3rd quarter valued at about $1,393,000. Finally, RTW Investments LP lifted its position in Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares during the last quarter. Hedge funds and other institutional investors own 60.00% of the company’s stock.

WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://weekherald.com/2017/12/04/arbutus-biopharma-abus-rating-lowered-to-sell-at-bidaskclub.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply